HGFAC

Hepatocyte growth factor activator serine protease · Q04756 · HGFAC on Sugi Atlas →

5,290 patent compounds predicted against HGFAC, 3,571 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5862728	0.46	7/20
Nafamostat (SCHEMBL135504)	1.00	4/20
Nafamostat (SCHEMBL1650158)	0.86	4/20
Hydrochloric Acid (SCHEMBL2357315)	0.46	4/20
Hydrochloric Acid (SCHEMBL2357318)	0.46	4/20
Hydrochloric Acid (SCHEMBL2358557)	0.46	4/20
SCHEMBL4399681	0.40	4/20
Camostat (SCHEMBL125270)	1.00	3/20
SCHEMBL240459	0.67	3/20
SCHEMBL1649708	0.64	3/20
Nitric Acid (SCHEMBL3860515)	0.63	3/20
SCHEMBL6417038	0.55	3/20
SCHEMBL1404357	0.54	3/20
N-(Ethoxycarbonyl)Piperazine (SCHEMBL3660147)	0.51	3/20
SCHEMBL4132832	0.50	3/20
Nitric Acid (SCHEMBL6034669)	0.47	3/20
N-(Ethoxycarbonyl)Piperazine (SCHEMBL3257068)	0.45	3/20
SCHEMBL2886812	0.45	3/20
SCHEMBL2886815	0.45	3/20
SCHEMBL5567267	0.45	3/20

Clinical trials — most relevant to HGFAC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
the Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant	PHASE4	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure	PHASE1/PHASE2	UNKNOWN
Resveratrol and Human Hepatocyte Function in Cancer	PHASE1/PHASE2	WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
STA-9090(Ganetespib) in Metastatic Ocular Melanoma	PHASE2	COMPLETED
Effect of Imatinib in Advance Liver Fibrosis Patients	PHASE1/PHASE2	UNKNOWN
Pazopanib and ARQ 197 for Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of HS-10241 in Solid Tumors	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.	nan	UNKNOWN
Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer	nan	UNKNOWN
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	nan	COMPLETED
Identification of Biomarkers for Early Detection of Pancreatic Cancer	nan	COMPLETED
Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Biomarkers in the Diagnosis and Prognosis of NAFLD	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HGFAC binder may also engage these)

Protein	Name	Similarity
Q6QNF4	—	0.998	Q6QNF4 →
O97507	—	0.997	O97507 →
D3ZTE0	—	0.996	D3ZTE0 →
F12	Coagulation factor XII	0.996	landscape →
Q9R098	—	0.995	Q9R098 →
Q80YC5	—	0.995	Q80YC5 →
P98140	—	0.992	P98140 →
Q04962	—	0.992	Q04962 →
F7	Coagulation factor VII	0.990	landscape →
Q24K22	—	0.990	Q24K22 →
Q2F9P2	—	0.989	Q2F9P2 →
Q9NPY3	—	0.988	Q9NPY3 →
P00743	—	0.987	P00743 →
TMPRSS6	Transmembrane protease serine 6	0.987	landscape →
P69526	—	0.986	P69526 →
Q7TQH7	—	0.985	Q7TQH7 →
Q2TV78	—	0.985	Q2TV78 →
Q9GLP2	—	0.984	Q9GLP2 →
P69525	—	0.984	P69525 →
Q9BYE2	—	0.984	Q9BYE2 →
Q8R0S6	—	0.984	Q8R0S6 →
P18292	—	0.984	P18292 →
Q7Z410	—	0.984	Q7Z410 →
Q3UZ09	—	0.984	Q3UZ09 →
MST1	Hepatocyte growth factor-like protein	0.984	landscape →
P15306	—	0.983	P15306 →
P00744	—	0.983	P00744 →
O95428	—	0.983	O95428 →
Q2F9P4	—	0.983	Q2F9P4 →
P22457	—	0.983	P22457 →